ASH 2022 | STIMULUS-MDS1: Phase II study of sabatolimab added to HMAs in high-risk MDS
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses the results from the primary results of STIMULUS-MDS1 trial (NCT03946670), which investigated the addition of sabatolimab to standard of care (SOC) hypomethylating agents (HMAs) in the first-line setting for patients with high-risk myelodysplastic syndromes (HR-MDS). Whilst the trial did not meet its primary endpoint, the study reported an encouraging safety profile for this combination. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Geron: Honoraria; Jazz: Honoraria; Abbvie: Honoraria; BMS/Celgene: Honoraria; Takeda: Honoraria; Novartis: Honoraria; Silence Therapeutics: Honoraria; Janssen: Honoraria.
